Clinical trial of new attenuated mumps virus vaccine (Jeryl Lynn strain) : preliminary report
Pagano, J.S.; Levine, R.H.; Sugg, W.C.; Finger, J.A.
Progress in immunobiological standardization 3: 196-202
1967
ISSN/ISBN: 0079-6344 PMID: 4908595 Document Number: 3205
In a controlled study of the effects of a new live virus mumps vaccine (Jeryl Lynn Strain) 2,965 school children in North Carolina were inoculated with the vaccine, and 329 children chosen randomly from the same population were given a placebo inoculation. The 2 groups were identified only on completion of the study. On the day of inoculation 34.9 % of the vaccinees and 37.1 % of the controls had a mumps neutralizing antibody titer of<1:2; these children were considered susceptible to mumps. One month later 98.1 % of the susceptible vaccinated children had had a 2-fold or greater rise in titer, and 85.6 %, a 4-fold or greater rise. In the placebo group 44 % of the susceptible children had a 2-fold or greater, and 22 %, a 4-fold or greater, rise in titer. There were no apparent clinical reactions to the vaccine. Eighteen cases of mumps occurred 31 to 180 days after inoculation, 5 in the vaccinated and 13 in the placebo-inoculated groups. The attack rates among children estimated to be at risk were 113 cases 0/00 in the controls and 4.98 cases ‰ in the vaccinated during this 5-month period. On this basis the protective efficacy of the vaccine against mumps was calculated to be 95.6 %.
Document emailed within 1 workday
